Brief: Medicinova Announces Additional Positive Results About Effects Of MN-001 On Serum Lipid Panel In Type 2 Diabetes And NAFLD Patients Presented At IDF 2022 Congress

Medicinova

06/12/2022 23:03

Dec 6 (Reuters) - MediciNova Inc  MNOV.O :
    * MEDICINOVA ANNOUNCES ADDITIONAL POSITIVE RESULTS REGARDING
THE
EFFECTS OF MN-001 (TIPELUKAST) ON SERUM LIPID PANEL IN TYPE 2
DIABETES AND NAFLD PATIENTS PRESENTED AT IDF 2022 CONGRESS, THE
ANNUAL MEETING OF THE INTERNATIONAL DIABETES FEDERATION
    * MEDICINOVA - MN-001 SIGNIFICANTLY REDUCED SERUM
TRIGLYCERIDES IN
PARTICIPANTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND
HYPERTRIGLYCERIDEMIA
    * MEDICINOVA INC - COMPARED TO SUBJECTS WITHOUT T2DM, T2DM
GROUP
SHOWED A GREATER REDUCTION IN SERUM TRIGLYCERIDE LEVELS AT WEEK
8

Source text for Eikon:  ID:nGNXbFWrRC 
Further company coverage:  MNOV.O 
 ((Reuters.Briefs@thomsonreuters.com;;))